Zogenix, Inc (NASDAQ: ZGNX) is a clinical stage pharmaceutical company committed to the development and commercialization of therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases. The company’s lead product candidate, ZX008, … Continue reading →

An announcement earlier this week from revenue-generating specialty pharmaceutical company Recro Pharma, Inc. (NASDAQ: REPH) is good news for those suffering from pain after major surgery. From its headquarters in Malvern, Pennsylvania, the company announced positive results from a phase … Continue reading →

New York-based Axsome Therapeutics, Inc. (NASDAQ: AXSM) is tending to a major and thriving market where current treatment options are insufficient. This young company (founded in 2012) is striving to establish a fully-integrated biopharmaceutical business that will develop and bring … Continue reading →

Chanticleer Holdings, Inc. (NASDAQ: HOTR) kicked off November with the announcement that, during the fiscal quarter ended September 30, 2016, the company achieved its second consecutive quarter of adjusted EBITDA profitability. This milestone came alongside an 18.3 percent year-over-year increase … Continue reading →

To paraphrase the renowned German playwright, Bertolt Brecht, nature does not remember kisses on the cheek. Wounds, on the other hand, perversely leave scars. Perhaps fortunately, kisses leave no mark, but injuries to the body do. And the scars of … Continue reading →

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of pharmaceutical products to help in the treatment of central nervous system disorders, now has a product portfolio made up of HETLIOZ® (tasimelteon), Fanapt® (iloperidone), Tradipitant … Continue reading →

In a recent news release by Professional Diversity Network, Inc. (NASDAQ: IPDN), it was announced that Cosmic Forward Limited (“CFL”), a Seychelles-based private company, now owns 51% of the Internet software and services company, which specializes in providing career networking … Continue reading →

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. The company’s development pipeline currently features … Continue reading →

Over 2,000 years ago, Plato, in his immortal Socratic dialogue, had the great philosopher express his astonishment at the new diseases plaguing Athenian society and their bizarre and horrible names. Our position today is very similar. Strange, horrible afflictions with … Continue reading →

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a company focused on the development of innovative treatments and therapies for cancer, in particular prostate cancer, recently released its financial results for the third quarter of 2016, reporting higher revenue and net income compared … Continue reading →